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found (odds ratios of 1.02, 1.019, 1.70, 1.04, 0.99 with p-values 0.79, 
0.3, 0.21, 0.88, 0.25 respectively in univariate analysis). We tested 
also whether our hypothesis is confirmed for the subset of patients 
with pre-treatment dyspnea grade 0 or 1, 124 (83.2%) patients, as high 
levels of dyspnea may well be due to congestive heart failure 
irrespective of RCHT. The results show an even higher odds ratio, 4.33 
(p-value < 0.001, 95% CI: 1.76-10.67), of maximal dyspnea ≥ 2 for 
patients with cardiac comorbidity. 
Figure 1. Frequency of RILT (measured by a CTCv3.0 dyspnea score 
within 6 months from the beginning of RCHT), for patients 
with/without cardiac comorbidity. The hypothesis that the odds ratio 
for post-RCHT dyspnea grade >=2 for the cardiac vs. no-cardiac 
comorbidity patients is equal to 1 is rejected (odds ratio = 3.65, p-
value <0.001, 95% CI = 1.70-7.81), total number patients = 149. 
 
 
Conclusions: Our results suggest that cardiac comorbidity is an 
important candidate factor for developing RILT after definite 
(chemo)radiotherapy of lung cancer patients. Therefore this 
observation should be further researched and externally validated.  
   
PD-0455   
Investigating a correlation between chemoradiotherapy schedule 
and survival in limited disease SCLC 
F. Manapov1, M. Niyazi1, F. Oskan1, G. Hildebrandt2, G. Klautke3, R. 
Fietkau4, C. Belka1 
1L.-Maximilians-Univ. Kl. Grosshadern, Radiation Oncology, München, 
Germany  
2University Hospital Rostock, Radiation Oncology, Rostock, Germany  
3Klinikum Sozial-Stiftung Bamberg, Radiation Oncology, Bamberg, 
Germany  
4University Hospital Erlangen, Radiation Oncology, Erlangen, Germany  
 
Purpose/Objective: Chemoradiotherapy (CRT) represents an actual 
treatment standard in limited disease small cell lung cancer (LD SCLC) 
and timing of thoracic irradiation (TRT) has been already the subject 
of randomised trials and meta-analyses. Several of them reported 
significantly improved overall survival (OS) when platinum-based early 
concurrent CRT is used. To investigate a correlation between CRT 
schedule and OS a temporal analysis of the multimodality treatment 
was performed in patients with LD SCLC. 
Materials and Methods: 182 patients with PS WHO 0-3 who 
successfully completed CRT were retrospectively reviewed. Thoracic 
radiation therapy (TRT) was applied in the concurrent or sequential 
mode. Influence of the treatment mode and interval of simultaneous 
treatment (IST) (IST – an interval in days when chemotherapy and TRT 
were applied simultaneously, including also time between 
chemotherapy cycles) on OS was analysed. 
Results: 70 (38%) patients were treated with concurrent and 112 (61%) 
with sequential CRT. Median survival (MS) for the entire cohort was 
536 days (95% CI: 462 – 609) without difference between the groups 
(concurrent 599 vs. sequential 532 days, p = 0.9, log-rank test). IST 
was 0 in 112 (61%) patients treated with sequential CRT whereas in 
the concurrent CRT group 29 (16%) and 42 (23%) patients showed an 
IST < 35 and >35, respectively. Patients with IST < 35 demonstrated a 
trend to better OS (MS: IST 0 vs. >35 vs. <35 was 533 vs. 448 vs. 1169 
days, p = 0.109, log-rank test). When patients treated with sequential 
CRT were excluded from the analysis, statistical difference in OS 
achieved significance (p = 0.021, log-rank test). In the multivariate 
analysis of patients treated with concurrent CRT, IST < 35 remained 
be significant variable correlating with better OS (p = 0.039, Cox 
regression). 
Conclusions: Temporal analysis of CRT schedule revealed that IST < 35 
can represent an important treatment-related parameter correlating 
with OS in patients with LD SCLC. By exceeding this interval we have 
seen no further improvement of OS due to concurrent application of 
the multimodality treatment. 
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Purpose/Objective: Delineation of the gross tumour volume (GTV) in 
esophageal cancer remains difficult. Moreover, to compensate for 
microscopic tumour spread, the current standard is to use relatively 
large margins (3-4 cm) from GTV to clinical target volume (CTV). The 
aim of this study was: (1) to analyse the accuracy of GTV delineation; 
(2) to analyse if the margins to the CTV were sufficient at pathologic 
examination after neo-adjuvant chemoradiotherapy (neo-CHRT), and: 
(3) to investigate if pathological findings after neo-CHRT influenced 
overall survival (OS).  
Materials and Methods: The study population was composed of 63 
esophageal cancer patients treated with neo-CHRT. In all patients, 
planning-CT scans were used combined with all diagnostic information 
to determine the GTV and CTV. During surgery, the GTV and CTV 
borders, as delineated on the planning-CT scans, were demarcated in 
situ at the esophagus in order to provide information regarding the 
exact location of macroscopic and microscopic tumour (see Figure). 
Demarcation points consisted of anatomical reference points that 
could be easily recognised both at CT and intraoperative (e.g. 
tracheal bifurcation, aortic arch, celiac trunk). To identify prognostic 
factors for OS, univariate and multivariate analysis were performed. 
Results: After resection, macroscopic residual tumour was found 
outside the GTV in 7 patients (11%). Microscopic residual tumour was 
located outside the CTV in nine patients (14%), in most cases caudally 
from the CTV. Three of these patients had an R1-resection, including 
2 with circumferential invasion and only 1 with invasion of the cranial 
and caudal borders. Six patients were partial responders, while three 
showed almost no response. The median follow up was 16.6 months 
(95% CI 14-19 months). In the univariate analysis, microscopic tumour 
extension outside the CTV, ypN+, lymphangio-invasion, perineural 
growth, lymph node ratio >0.10 and >5 positive lymph nodes were 
associated with worse OS. In the multivariate analysis, only 
microscopic tumour extension outside the CTV (HR 4.96, 95%CI 1.03-
15.36) and perineural growth (HR 5.77, 95%CI 1.27-26.13) were 
identified as independent adverse prognostic for OS. Without tumour 
outside the CTV the 1 year OS was 86% vs. 20% for patients with 
tumour outside the CTV (p=<0.01). 
Conclusions: Despite using advanced pre-RT imaging and neo-CHRT, 
(1) macroscopic tumour outside the GTV was found in 11% of the 
patients and (2) microscopic tumour foci outside the CTV in 14% of the 
cases (mainly caudally from the CTV). (3) Moreover, the presence of 
microscopic tumour spread beyond CTV borders had a significant and 
major adverse impact on OS. These findings emphasize the 
importance of accurate delineation of the GTV and indicate that 
currently used margins from GTV to CTV in particular in caudal 
direction are not sufficient which may adversely impact treatment 
outcome.  
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Purpose/Objective: The main weakness of the radiotherapy workflow 
is undoubtly the GTV delineation. It is therefore important to validate 
automated segmentation methods in 2D but even better in 3D. FDG 
uptake within a tumor, assessed with PET-imaging, can be used to 
automatically create a tumor contour using standardized uptake value 
(SUV) thresholding. It has already been shown that the tumor length 
measured in the surgical specimen correlates highly with a PET-based 
autocontour. The goal of this study was to validate the volume of an 
automatic generated PET-based tumor contour with pathology for 
rectal cancer. 
Materials and Methods: Eight patients diagnosed with non-locally 
advanced rectal cancer (NLARC), referred for pre-operative treatment 
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with short course hypofractionated radiotherapy (RT) were included in 
this study. Pre-operative treatment with RT was followed by a total 
mesorectal excision (TME) within 3 days after the last RT fraction. For 
each patient, a FDG-PET-CT scan was performed prior to the start of 
treatment. The tumor was automatically delineated from the PET-
images using SUV-thresholding, with the threshold depending on the 
tumor-to-background signal ratio. The volume of the PET-based tumor 
contour was validated by pathological examination of the resected 
specimen. For this validation, the resected specimen was sliced into 5 
mm slices and each slice was photographed. On the photographs, the 
tumor was manually delineated by the pathologist. The tumor volume 
was calculated by multiplying the tumors surface area with the slice 
thickness of 5 mm. Automatic delineation with other methods, 
including watershed based clustering, will be presented. 
Results: Automatic SUV-threshold based tumor delineation resulted in 
an average tumor volume of 16.2±11.3 cm3 (range: 7.7 to 38.7 cm3), 
whereas pathological examination of the resected specimens resulted 
in an average tumor volume of 16.0±11.5 cm3 (range: 7.8 to 36.5 cm3). 
The average volume difference was 2±2.0 cm3 (range: -2.2 to 3.0 
cm3). A correlation coefficient of 0.964 (p<0.001) was found when 
correlating the tumor volumes resulting from PET-analysis and 
pathological examination. 
Conclusions: The strong correlation between the tumor volumes 
resulting from SUV-thresholding of PET-images and pathological 
examination of the surgical specimen demonstrates the accuracy of 
automatic PET-based tumor delineation based on SUV-thresholding for 
patients diagnosed with rectal cancer. This unique 3D dataset will be 
used as golden standard for the comparison of multiple PET-based 
automatic segmentation algorithms. 
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Purpose/Objective: The clinical utility of alpha-fetoprotein (AFP) as a 
predictor of treatment outcome in patients with advanced HCC 
receiving stereotactic body radiotherapy (SBRT) has been poorly 
defined. We aimed to study the clinical value of AFP response in an 
attempt to validate it as a surrogate serologic end point. 
Materials and Methods: We analyzed the prospectively collected data 
of 53 locally advanced HCC patients with elevation of AFP (>20) 
received individualized hypofractionated radiotherapy using 
stereotactic body radiotherapy (SBRT) technique between 2006 and 
2011. AFP response defined as >50% decrease from baseline, 3 months 
after the completion of SBRT. Radiological response rate was assessed 
by CT scan using RECIST criteria.  
Results: Median follow-up time was 11.2 months. Patients' 
characteristics were as follows: Median age (62 years, range: 36-86); 
Male/ female (n= 44/9 respectively); Child-Pugh class A/B (n= 45/8 
respectively); and portal vein thrombosis (n=23). Individualized 
hypofractionated radiotherapy using SBRT technique was given at 4Gy 
per fraction, range from 5-10 fractions, with the median dose of 32Gy 
was delivered. The overall response rate was 39.6%. The median 
overall survival (OS) and progression free survival (PFS) was 11.2 
months and 5.4 months respectively. AFP responders (n= 22) had 
better objective response rate than AFP non-responders (n=31) after 
SBRT (59.1 vs. 25.8%; P=0.01). Median OS rate was longer in AFP 
responders (17.9 vs 9.0 months, p=0.02). Median PFS rate was also 
longer in AFP responder than AFP non-responders although it was not 
statistically significant. (PFS, 7.0 vs 5.1 months, p= 0.18). In 
multivariate analysis, AFP response was independent factor affecting 
OS (hazard ratio, 2.46; 95% CI, 1.07 to 5.68; p=0.035). Of the 29 
patients with radiological stable disease (SD), AFP responders (n=9) 
had a better 1-year survival rate than AFP non-responders (n=20) 
(66.7% vs 31.9%, p=0.049). 
Figure 1. Overall survival (OS) of AFP responders and AFP non-
responders 
 
Conclusions: AFP response is useful in predicting prognosis and 
treatment response in patients with advanced HCC received SBRT. 
Incorporation of AFP response into the criteria of evaluating the 
outcome of SBRT should be considered. Additional treatment may 
require in the AFP non-responders. 
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Purpose/Objective: To investigate the possible benefit deriving from 
whole pelvis radiotherapy (WPRT) in combination with high-dose 
salvage radiotherapy (HDSRT) in the salvage treatment of node-
negative patients experiencing a biochemical recurrence (BR) after 
radical prostatectomy (RP) and pelvic lymphoadenectomy. 
Materials and Methods: From 1998 to 2008, 208 node-negative 
(median 11 LN) patients (pts) underwent HDSRT at 1.8 Gy/fraction to 
the prostatic bed (PB) only (n=138, median dose 73.8 Gy) or to WPRT 
(n=70, median dose 50.4 Gy) followed by a boost to PB (median dose 
75.6 Gy). All pts underwent 3DCRT technique except for 28 who 
received WPRT-IMRT followed by a 3DCRT boost to PB. 
Patients characteristics were comparable in terms of preoperative 
PSA, pT, surgical margins, Gleason score (GS), median time to BR 
after RP (overall 21.5 months), median PSA doubling time (PSADT, 
overall 8.9 months), PSA at SRT (PSA@SRT, overall 0.70 ng/mL) and 
fraction of pts receiving neoadjuvant (NAD) or adjuvant androgen 
deprivation (AAD) in addition to SRT. The 2 groups differed 
significantly in terms of median follow-up (FU, 102 vs 73 months, 
owing to the gradual introduction of WPRT over time), fraction of 
biopsy confirmed local relapse (49% vs 31%), length of AAD (10 vs 15 
months) and median RT dose (73.8 vs 75.6 Gy) in PB vs WPRT+PB 
group, respectively.  
Results: After a median FU of 87 months, WPRT+PB resulted in a 
significant improvement of 7-year biochemical relapse-free survival 
(bRFS) when compared to PB only both in the overall population (86 vs 
67%, p=0.02) and in the subset of the 134 pts with a PSA@SRT ≤1 
ng/mL (90 vs 69%, p=0.02). The other factor predictive of improved 
bRFS at univariate analysis (UA) in both subgroups was RT dose (p-
value always <0.0001, most informative cut-off <73.8 Gy in both 
cohorts). Radiation doses ≥75.6 Gy resulted in improved 7-year bRFS 
both in the overall population (87% vs 63%, p<0.0001) and in pts with 
PSA@SRT ≤1 ng/mL (85% vs 65%, p=0.002). In the overall population, 
pT and PSADT (but not NAD nor AAD) were also significant predictors 
of bRFS at UA. At multivariate analysis, in the overall population 
PSA@SRT, RT dose ≤73.8 Gy, PB only irradiation and GS 7-10 (and in 
the subset with PSA@SRT ≤1 ng/mL, PB only RT and and GS ≥8) 
independently predicted treatment failure. Overall, HDSRT resulted in 
only mild acute and late genitourinary (GU) and gastrointestinal (GI) 
toxicity (TOX), without significant differences between WPRT+PB or 
PB subgroups. Of note, WPRT resulted in a doubling of acute intestinal 
G2 TOX (15 vs 7%), a finding which disappeared when only pts treated 
